Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
University of Cincinnati, Cincinnati, Ohio Australia
Royal Prince Alfred Hospital, Camperdown, New South Wales Royal Adelaide Hospital, Adelaide, South Australia Brazil
Fundação Oswaldo Ramos - Hospital do Rim, São Paulo Canada
Providence Health Care - St. Paul's Hospital, Vancouver, British Columbia Vancouver General Hospital, Vancouver, British Columbia McGill University Health Care Centre, Montreal, Quebec United Kingdom
Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital, Liverpool Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital, Oxford